Stockscreener 앱 받기
48.76
3.52%
1.66
시간 외 거래:
48.76
전일 마감가:
$47.10
열려 있는:
$47.72
하루 거래량:
73,424
Relative Volume:
1.19
시가총액:
$134.20M
수익:
$697.00K
순이익/손실:
$-37.19M
주가수익비율:
-1.2935
EPS:
-37.6952
순현금흐름:
$-29.34M
1주 성능:
+3.46%
1개월 성능:
-9.33%
6개월 성능:
-35.71%
1년 성능:
-90.34%
1일 변동 폭
$46.49
$51.60
1주일 범위
$46.49
$53.25
52주 변동 폭
$7.26
$543.38
스프루스 바이오 Stock (SPRB) Company Profile
명칭
Spruce Biosciences Inc
전화
(415) 655-4168
주소
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
48.76 | 137.35M | 697.00K | -37.19M | -29.34M | -37.70 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
스프루스 바이오 Stock (SPRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | Craig Hallum | Buy |
| 2025-12-23 | 개시 | Oppenheimer | Outperform |
| 2025-12-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-03-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | 개시 | Guggenheim | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | The Benchmark Company | Speculative Buy |
| 2021-11-16 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | 개시 | H.C. Wainwright | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2020-11-03 | 개시 | SVB Leerink | Outperform |
모두보기
스프루스 바이오 주식(SPRB)의 최신 뉴스
BBIO Welcomes New Leadership in Marketing and Finance - GuruFocus
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller - Investing News Network
Spruce Biosciences names two executives ahead of potential FDA decision - Investing.com
Spruce Biosciences Appoints Eric Jordan and Tina Gullotta to Leadership Roles Ahead of Potential TA-ERT Launch - citybiz
Spruce Biosciences names two executives ahead of potential FDA decision By Investing.com - Investing.com Canada
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
SPRB Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentEarnings Cycle Outlook - newsline.com
SPRB News | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
SPRB Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential By Investing.com - Investing.com Australia
Spruce Biosciences (SPRB) Reports Promising Long-Term Results fo - GuruFocus
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential - Investing.com UK
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B Presented at the 18th International MPS Symposium - Investing News Network
Spruce says long-term TA-ERT data presented at MPS Symposium - TipRanks
Spruce Biosciences stock rises on MPS IIIB data, analyst initiation - Investing.com
Spruce Biosciences stock rises on MPS IIIB data, analyst initiation By Investing.com - Investing.com India
Spruce presents six-year data on MPS IIIB therapy candidate By Investing.com - Investing.com Nigeria
Spruce Biosciences (SPRB) Reports Promising Long-Term Results for Enzyme Therapy - GuruFocus
Spruce presents six-year data on MPS IIIB therapy candidate - Investing.com
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium - Business Wire
Spruce Biosciences (SPRB) Edges Lower Amid Consolidation PhaseChart Pattern Alerts - newsline.com
SPRB Technical Analysis | Trend, Signals & Chart Patterns | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Spire Global, Inc. (SPIR) Is Up 7.94% in One Week: What You Should Know - Yahoo Finance
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $150 - Moomoo
SPRB Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $150 - GuruFocus
Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright - TipRanks
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium - BioSpace
Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium - TradingView
Spruce Biosciences to Participate in Upcoming Conferences in June 2026 - BioSpace
Spruce Biosciences to Participate in Upcoming Conferences in June - Investing News Network
Spruce Biosciences Stockholders Approve Directors and Annual Say-on-Pay - The Globe and Mail
Oppenheimer Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $230 - Moomoo
Oppenheimer lowers Spruce Biosciences stock price target to $230 By Investing.com - Investing.com South Africa
Oppenheimer lowers Spruce Biosciences stock price target to $230 - Investing.com
Spruce Biosciences (SPRB) director granted 1,700 stock options at 52.70 - Stock Titan
Director Camilla V. Simpson awarded 1,700 SPRB options at $52.70 strike - Stock Titan
Spruce Biosciences (SPRB) chair receives grant of 1,700 stock options - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) grants director 1,700 options - Stock Titan
Spruce Biosciences (SPRB) grants director Keli Walbert 1,700 options - Stock Titan
Spruce Biosciences (SPRB) 2026 annual meeting and say-on-pay votes - Stock Titan
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy - Yahoo Finance
Spruce Biosciences Inc (SPRB) Stock Price, Quote, News & History - Benzinga
SPRB: Directors elected, all proposals approved, and strategic plans funded for regulatory milestones - TradingView
SPRB: All proposals passed, with updates on financing, manufacturing, and regulatory milestones shared - TradingView
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade - MSN
Is Spruce Biosciences (SPRB) Overvalued After Q1 2026 EPS Beat? - GuruFocus
Citadel entities, Kenneth Griffin hold ~5.1% of Spruce Biosciences (SPRB) - Stock Titan
스프루스 바이오 (SPRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
스프루스 바이오 주식 (SPRB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 15 '25 |
Option Exercise |
0.00 |
1,009 |
0 |
8,447 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 15 '25 |
Option Exercise |
0.00 |
2,676 |
0 |
14,922 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 11 '25 |
Option Exercise |
0.00 |
1,900 |
0 |
8,296 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '25 |
Option Exercise |
0.00 |
514 |
0 |
6,580 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 11 '25 |
Option Exercise |
0.00 |
4,950 |
0 |
15,192 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '25 |
Option Exercise |
0.00 |
1,196 |
0 |
10,670 |
| Gharib Samir M. | PRESIDENT AND CFO |
Oct 20 '25 |
Option Exercise |
0.00 |
2,053 |
0 |
6,727 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Oct 20 '25 |
Option Exercise |
0.00 |
4,784 |
0 |
11,013 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
2.60%
0.94%
자본화:
|
볼륨(24시간):